Galapagos announces start of Phase 2 study with selective TY

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Related Keywords

Belgium , Japan , Mechelen , Region Flamande , Marieke Vermeersch , Daniele Dambrosio , Sandra Cauwenberghs , Van Gijsel , British Isles Lupus Assessment Group , Exchange Commission , Composite Lupus Assessment , Cutaneous Lupus Erythematosus Disease Area , Severity Index Activity , Lupus Low Disease Activity State , Danieled Ambrosio , Therapeutic Area Head Immunology ,